Evidence map›Paper›PMID 37341186›Full record

ArticleBiochemistry2023

Irreversible Inactivation of SARS-CoV-2 by Lectin Engagement with Two Glycan Clusters on the Spike Protein.

Aakansha Nangarlia, Farah Fazloon Hassen, Gabriela Canziani, Praneeta Bandi, Choya Talukder, Fengwen Zhang, Douglas Krauth, Ebony N Gary, David B Weiner, Paul Bieniasz and 4 more

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Aakansha NangarliaDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.ORCID 0000-0003-2796-9092
Farah Fazloon HassenDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.
Gabriela CanzianiDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.
Praneeta BandiDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.
Choya TalukderDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.
Fengwen ZhangLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, United States.
Douglas KrauthDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.
Ebony N GaryThe Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
David B WeinerThe Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania 19104, United States.
Paul BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, New York 10065, United States.
Sonia Navas-MartinDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.
Barry R O'KeefeMolecular Targets Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland 21702, United States.ORCID 0000-0003-0772-4856
Charles G AngDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.ORCID 0000-0002-2368-552X
Irwin ChaikenDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, United States.ORCID 0000-0002-2996-2030
Drexel University · USHoward Hughes Medical Institute · USThe Wistar Institute · USInstitute for Molecular Medicine · USTarget (United States) · US

Funding

Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI HENDRICKSON, WAYNE A. · 1997 to 2018
$31.2M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
Assay development and screening for molecular targets and discoveryZIABC011904 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, BRICE · 2019 to 2025
$12.8M
Isolation of bioactive proteins from natural product extractsZIABC011472 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2012 to 2025
$7.8M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01AI150471 · NIAID · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M, MOTHES, WALTHER H · 2019 to 2022
$7.8M
NCI Program for Natural Products Discovery - CuresZIABC011854 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2020 to 2025
$5.2M
A TLR3-STAT3-miR-155 axis and astrocyte-myeloid crosstalk in viral encephalitisR01NS104365 · NINDS · DREXEL UNIVERSITY · PI NAVAS-MARTIN, SONIA · 2018 to 2022
$1.7M
Biacore S200 Surface Plasmon Resonance Instrument for a Shared Resources FacilityS10OD027009 · OD · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M · 2019 to 2019
$365k
Intramural NIH HHS ZIA BC011854Intramural NIH HHS ZIA BC011904NCI NIH HHS T32 CA009171NIAID NIH HHS P01 AI150471NIGMS NIH HHS P01 GM056550NIH HHS S10 OD027009NINDS NIH HHS R01 NS104365
6 · The paper itself

Abstract

Host cell infection by SARS-CoV-2, similar to that by HIV-1, is driven by a conformationally metastable and highly glycosylated surface entry protein complex, and infection by these viruses has been shown to be inhibited by the mannose-specific lectins cyanovirin-N (CV-N) and griffithsin (GRFT). We discovered in this study that CV-N not only inhibits SARS-CoV-2 infection but also leads to irreversibly inactivated pseudovirus particles. The irreversibility effect was revealed by the observation that pseudoviruses first treated with CV-N and then washed to remove all soluble lectin did not recover infectivity. The infection inhibition of SARS-CoV-2 pseudovirus mutants with single-site glycan mutations in spike suggested that two glycan clusters in S1 are important for both CV-N and GRFT inhibition: one cluster associated with the RBD (receptor binding domain) and the second with the S1/S2 cleavage site. We observed lectin antiviral effects with several SARS-CoV-2 pseudovirus variants, including the recently emerged omicron, as well as a fully infectious coronavirus, therein reflecting the breadth of lectin antiviral function and the potential for pan-coronavirus inactivation. Mechanistically, observations made in this work indicate that multivalent lectin interaction with S1 glycans is likely a driver of the lectin infection inhibition and irreversible inactivation effect and suggest the possibility that lectin inactivation is caused by an irreversible conformational effect on spike. Overall, lectins' irreversible inactivation of SARS-CoV-2, taken with their breadth of function, reflects the therapeutic potential of multivalent lectins targeting the vulnerable metastable spike before host cell encounter.

Indexed as

COVID-19LectinsAntiviral AgentsHumansPolysaccharidesSARS-CoV-2Spike Glycoprotein, CoronavirusAntiviral AgentsLectinsPolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID37341186
PMCPMC10663058
OpenAlexW4381469393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.